News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,108 Results
Type
Article (40871)
Company Profile (267)
Press Release (679960)
Multimedia
Podcasts (80)
Webinars (17)
Section
Business (204653)
Career Advice (2022)
Deals (35532)
Drug Delivery (110)
Drug Development (81369)
Employer Resources (173)
FDA (16402)
Job Trends (14941)
News (346347)
Policy (32721)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2565)
Accelerated approval (31)
Adcomms (24)
Allergies (137)
Alliances (49576)
ALS (167)
Alzheimer's disease (1658)
Antibody-drug conjugate (ADC) (305)
Approvals (16667)
Artificial intelligence (500)
Autoimmune disease (143)
Automation (37)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (187)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (55)
Breast cancer (632)
Cancer (4751)
Cardiovascular disease (395)
Career advice (1707)
Career pathing (35)
CAR-T (275)
CDC (44)
Celiac Disease (2)
Cell therapy (728)
Cervical cancer (36)
Clinical research (69490)
Collaboration (1666)
Company closure (4)
Compensation (1141)
Complete response letters (52)
COVID-19 (2707)
CRISPR (87)
C-suite (810)
Cystic fibrosis (143)
Data (6151)
Decentralized trials (2)
Denatured (25)
Depression (130)
Diabetes (495)
Diagnostics (6669)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (241)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (226)
Earnings (90036)
Editorial (55)
Employer branding (21)
Employer resources (151)
Events (117177)
Executive appointments (958)
FDA (19475)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (23)
Funding (1444)
Gene editing (191)
Generative AI (42)
Gene therapy (582)
GLP-1 (962)
Government (4651)
Grass and pollen (6)
Guidances (383)
Healthcare (18868)
HIV (55)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (244)
Immuno-oncology (53)
Indications (103)
Infectious disease (2965)
Inflammatory bowel disease (186)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (242)
Interviews (315)
IPO (16639)
IRA (49)
Job creations (3641)
Job search strategy (1427)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (545)
Leadership (30)
Legal (7948)
Liver cancer (91)
Longevity (14)
Lung cancer (639)
Lymphoma (371)
Machine learning (42)
Management (59)
Manufacturing (776)
MASH (161)
Medical device (13754)
Medtech (13806)
Mergers & acquisitions (19950)
Metabolic disorders (1251)
Multiple sclerosis (156)
NASH (16)
Neurodegenerative disease (307)
Neuropsychiatric disorders (86)
Neuroscience (2865)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4509)
Now hiring (65)
Obesity (587)
Opinion (256)
Ovarian cancer (164)
Pain (196)
Pancreatic cancer (222)
Parkinson's disease (279)
Partnered (33)
Patents (486)
Patient recruitment (471)
Peanut (55)
People (58806)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21665)
Phase 2 (30584)
Phase 3 (22789)
Pipeline (5084)
Policy (278)
Postmarket research (2564)
Preclinical (9190)
Press Release (64)
Prostate cancer (234)
Psychedelics (47)
Radiopharmaceuticals (277)
Rare diseases (814)
Real estate (5953)
Recruiting (69)
Regulatory (24411)
Reports (51)
Research institute (2383)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (146)
Series A (237)
Series B (184)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3612)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (53)
Vaccines (983)
Venture capital (86)
Weight loss (377)
Women's health (87)
Worklife (18)
Date
Today (22)
Last 7 days (600)
Last 30 days (1961)
Last 365 days (29744)
2026 (2833)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32108)
2016 (31484)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (305)
Arkansas (13)
Asia (39187)
Australia (6405)
California (11154)
Canada (3250)
China (1082)
Colorado (471)
Connecticut (469)
Delaware (332)
Europe (84415)
Florida (1661)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (851)
India (62)
Indiana (513)
Iowa (22)
Japan (417)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1369)
Massachusetts (7991)
Michigan (319)
Minnesota (622)
Mississippi (5)
Missouri (125)
Montana (31)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2967)
New Mexico (28)
New York (2941)
North Carolina (1436)
North Dakota (8)
Northern California (5435)
Ohio (329)
Oklahoma (21)
Oregon (41)
Pennsylvania (2252)
Puerto Rico (22)
Rhode Island (47)
South America (1107)
South Carolina (65)
South Dakota (1)
Southern California (4340)
Tennessee (172)
Texas (1722)
United States (39549)
Utah (333)
Vermont (1)
Virginia (256)
Washington D.C. (81)
Washington State (913)
West Virginia (4)
Wisconsin (106)
Wyoming (2)
721,108 Results for "neurometrix inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
NeuroMetrix Reports Q1 2024 Business Highlights
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2024.
May 15, 2024
·
5 min read
Business
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
NeuroMetrix, Inc. announced that it plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.
February 15, 2024
·
1 min read
Genetown
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
NeuroMetrix, Inc. announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders, Ephraim Fields of Echo Lake Capital.
April 19, 2024
·
2 min read
Press Releases
NeuroMetrix to be Acquired by electroCore
December 17, 2024
·
8 min read
Business
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023.
February 22, 2024
·
7 min read
Genetown
NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024
NeuroMetrix, Inc. (Nasdaq: NURO), announced today that it will present at the Emerging Growth Conference on January 10, 2024.
January 8, 2024
·
2 min read
Genetown
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
NeuroMetrix, Inc. noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck alone accurately detects diabetic peripheral neuropathy.
March 14, 2024
·
2 min read
Business
NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call
NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26, 2023.
October 23, 2023
·
1 min read
Genetown
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value
NeuroMetrix, Inc. announced a process to review strategic options to promote growth of its Quell® neuromodulation and DPNCheck® neurodiagnostic businesses and to maximize shareholder value.
February 13, 2024
·
2 min read
Genetown
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
NeuroMetrix, Inc. (NASDAQ: NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in December 2022.
March 13, 2024
·
2 min read
1 of 72,111
Next
